Premium
Drug Interactions Should Be Evaluated in Patients
Author(s) -
Fletcher C V
Publication year - 2010
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1038/clpt.2010.213
Subject(s) - clinical pharmacology , drug , pharmacodynamics , medicine , pharmacology , pharmacokinetics , drug interaction , drug drug interaction , drug development , intensive care medicine
Drug development involves learning and confirming in healthy volunteers and ultimately in patients. This approach should apply to drug–drug interactions because requirements to extrapolate pharmacokinetic and pharmacodynamic findings from healthy volunteers to patients are not uniformly met, and the designs of interaction studies often have little relevance to actual clinical use. Guidance to health‐care professionals on a safe and effective dose for individual patients should include information from drug–drug interaction studies in the intended patients. Clinical Pharmacology & Therapeutics (2010) 88 5, 585–587. doi: 10.1038/clpt.2010.213